{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:42:42Z","timestamp":1773160962865,"version":"3.50.1"},"reference-count":10,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.2967\/jnumed.121.262361","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T15:56:15Z","timestamp":1622217375000},"page":"166.2-166","source":"Crossref","is-referenced-by-count":5,"title":["Potential Theranostic Role of Bone Marrow Glucose Metabolism on Baseline <sup>18<\/sup>F-FDG PET\/CT in Metastatic Melanoma"],"prefix":"10.2967","volume":"63","author":[{"given":"Romain-David","family":"Seban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Champion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izza","family":"Muneer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shwe","family":"Synn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Dercle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"2022032309401352000_63.1.166-b.1","doi-asserted-by":"crossref","unstructured":"Nakamoto R Zaba LC Liang T . Prognostic value of bone marrow metabolism on pretreatment 18 F-FDG PET\/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. J Nucl Med. February 5, 2021 [Epub ahead of print].","DOI":"10.2967\/jnumed.120.254482"},{"key":"2022032309401352000_63.1.166-b.2","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.2967\/jnumed.120.242768","article-title":"Diagnosis of hyperprogressive disease in patients treated with checkpoint inhibitors using 18F-FDG PET\/CT","volume":"61","author":"Seban","year":"2020","journal-title":"J Nucl Med."},{"key":"2022032309401352000_63.1.166-b.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193011"},{"key":"2022032309401352000_63.1.166-b.4","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","article-title":"Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics","volume":"46","author":"Seban","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022032309401352000_63.1.166-b.5","first-page":"559","article-title":"Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer","volume":"47","author":"Pr\u00e9vost","year":"2006","journal-title":"J Nucl Med."},{"key":"2022032309401352000_63.1.166-b.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.216697"},{"key":"2022032309401352000_63.1.166-b.7","doi-asserted-by":"crossref","first-page":"e1408750","DOI":"10.1080\/2162402X.2017.1408750","article-title":"Melanoma induced immunosuppression is mediated by hematopoietic dysregulation","volume":"7","author":"Kamran","year":"2017","journal-title":"OncoImmunology."},{"key":"2022032309401352000_63.1.166-b.8","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/s41598-021-81298-1","article-title":"Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer","volume":"11","author":"Shimura","year":"2021","journal-title":"Sci Rep."},{"key":"2022032309401352000_63.1.166-b.9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0008"},{"key":"2022032309401352000_63.1.166-b.10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00262-018-2175-3","article-title":"Targeting myeloid-derived suppressor cells for cancer immunotherapy","volume":"67","author":"Liu","year":"2018","journal-title":"Cancer Immunol Immunother."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.262361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T16:40:32Z","timestamp":1648053632000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.262361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,3]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.2967\/jnumed.121.262361"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.262361","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]}}}